M&A Deal Summary

ADVANZ PHARMA Acquires Correvio Pharma

On March 16, 2020, ADVANZ PHARMA acquired life science company Correvio Pharma for 76M USD

Acquisition Highlights
  • This is ADVANZ PHARMA’s 4th transaction in the Life Science sector.
  • This is ADVANZ PHARMA’s 4th largest (disclosed) transaction.
  • This is ADVANZ PHARMA’s 1st transaction in Canada.
  • This is ADVANZ PHARMA’s 1st transaction in British Columbia.

M&A Deal Summary
Date 2020-03-16
Target Correvio Pharma
Sector Life Science
Buyer(s) ADVANZ PHARMA
Deal Type Add-on Acquisition
Deal Value 76M USD
Advisor(s) Piper Sandler & Co. (Financial)
Blake, Cassels & Graydon
Skadden, Arps, Slate, Meagher & Flom (Legal)

Target

Correvio Pharma

Vancouver, British Columbia, Canada
Correvio Pharma Corp. is a specialty pharmaceutical company dedicated to the development and commercialization of cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease. Correvio Pharma is headquartered in Vancouver, Canada.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

ADVANZ PHARMA

London, United Kingdom
Category Company
Founded 1963
Sector Life Science
Employees675
Revenue 508M USD (2019)
DESCRIPTION

ADVANZ PHARMA is a specialty pharmaceutical company with a strategic focus on complex medicines with direct sales access in Europe and a global distribution network. ADVANZ PHARMA was founded in 1963 and is based in London, United Kingdom.

DEAL STATS #
Overall 6 of 6
Sector (Life Science) 4 of 4
Type (Add-on Acquisition) 3 of 3
State (British Columbia) 1 of 1
Country (Canada) 1 of 1
Year (2020) 1 of 1
Size (of disclosed) 4 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-04-01 Eisai - Two Medicines

Woodcliff Lake, New Jersey, United States

Eisai, Inc. - Two Medicines (Salagen & Panretin) is a pharmaceutical business, Salagen® indications include the treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck, and the treatment of symptoms of dry mouth in patients with Sjogren's Syndrome. Panretin® indications include the topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma (KS).

Buy $33M
Mergr

Product

Company

Legal